This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Actelion Pharmaceuticals Ltd.
Drug Names(s): Vevesca, miglustat, OGT-918, Brazaves (Japan)
Description: Zavesca is in a class of drugs known as substrate reduction therapy (SRT). The drug reduces the rate of formation of glucosylceramide, the first intermediate in the synthesis of a large family of glycosphingolipid (GSL) that accumulates in Gaucher's Disease (GD), to a level that can be cleared by the remaining glucocerebrosidase enzyme. This prevents the build up of excess glucosylceramide and other GSLs in the cells of the reticuloendothelial system.
Zavesca also has evidence for correcting the defective trafficking of F508del-CFTR, a common mutation in cystic fibrosis.
Actelion and Oxford GlycoSciences
In November 2002, Actelion entered into a licenseagreement with Oxford GlycoSciences (OGS) for Zavesca. OGS has since been acquired by Celltech, which was subsequently acquiredby UCB. The Group has been granted exclusivemarketing rights to sell Zavesca in all countries except Israel and the adjacent West Bank and Gaza Strip territories where the Group will ensure the drug supply to Teva. In addition, the Group assumed full responsibilityfor manufacturing and supply chain, patent-related activities, clinical and pre-clinical activities of Zavesca. The Group made payments of EUR 7.5 million (CHF 11.7 million) to UCB,which were capitalized as an intangible asset and amortized over the patent life, in exchange for a single-digit royalty rate on future Zavesca sales in glycosphingolipid (GSL) storage disorders.
Actelion and UCB
Actelion and UCB announced in November 2005 that the two companies replaced their previous license...See full deal structure in Biomedtracker
Partners: Teva Pharmaceutical Industries Ltd. UCB SA Biotoscana International
Additional information available to subscribers only: